Seqens, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced strengthened ties with the Greater Boston life sciences community with the signing of a dozen local biotech and medtech customers.
“This year has been one of tremendous growth for Seqens,” said Ed Price, President of Seqens. “We’re reached major milestones with customers, products, staff and awards, testament to the quality of our work and our commitment to put the customers first.”
Local partnerships have been a growing trend in the industry and in Seqens’s business as well. According to Price, “Emerging pharma customers prefer the ease and practicality of working locally with partners such as Seqens. There is greater collaboration, a faster buildup of trust and overall better communication when you work with a local partner as compared to a business located somewhere overseas or in a different time zone. The end result? A better product, saved time, and saved money – tangible benefits that customers appreciate.”
Many of Seqens’s newest customers are just a short drive from the company’s Newburyport and Devens facilities, making it easy for customers to see the manufacturing in action and check on the status of their project. Seqens stands apart from other contract manufacturing organizations because of its disciplined, proactive and focused project management approach, where transparency and accountability are built into every detailed project plan, milestone and communication.
“Unfortunately, that is not always the case with other CMOs, yet it is critically important for our customers,” Price explained. “They want the job done right the first time, but that is not always their experience elsewhere. I believe that is another strong reason we have a record number of referrals.”
Seqens expects the commercialization of two products this year, active ingredients in generic drugs. To meet the demand in new customers and products in the pipeline, the company now stands at more than 110 employees, an increase of 22 percent over last year. It is actively hiring for a variety of new positions.
Due to this momentum and its growing reputation, Seqens was recently recognized as a Life Science Leader CMO Leadership Award recipient for the second year in a row in multiple categories. It won regulatory awards for both the midsize pharma and biotech industry sectors. The company has now won the top spot in every category in which the awards are given.
Seqens is a custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), Seqens provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in generic pharmaceuticals. To learn more about Seqens, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.